David P. Carbone

David P. Carbone

Auto-generated profile, based on publicly available information

David P. Carbone

Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute, Columbus, Ohio, United States

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DCDavid P. Carbone
David P. Carbone
MRMartin Reck
Martin Reck
LPLuis Paz-Ares
Luis Paz-Ares
BCBenjamin Creelan
Benjamin Creelan
LHLeora Horn
Leora Horn
MSMark A. Socinski
Mark A. Socinski
Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)–positive NSCLC. We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533.)

12 September 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JCJamie E. Chaft
Jamie E. Chaft
FOFiliz Oezkan
Filiz Oezkan
MKMark G. Kris
Mark G. Kris
PBPaul A. Bunn
Paul A. Bunn
IWIgnacio I. Wistuba
Ignacio I. Wistuba
JBJustin D. Blasberg
Justin D. Blasberg
In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 patients in the primary end point analysis, the MPR was 20% (95% confidence interval, 14–28%). With a minimum duration of follow-up of 3 years, the 3-year survival rate of 80% was encouraging. The most common adverse events during the neoadjuvant phase were fatigue (39%, 71 of 181) and procedural pain (29%, 53 of 181), along with expected immune-related toxicities; there were no unexpected safety signals. In exploratory analyses, MPR was predicted using the pre-treatment peripheral blood immunophenotype based on 14 immune cell subsets. Immune cell subsets predictive of MPR in the peripheral blood were also identified in the tumor microenvironment and were associated with MPR. This study of neoadjuvant atezolizumab in a large cohort of patients with resectable non-small cell lung cancer was safe and met its primary end point of MPR ≥ 15%. Data from this single-arm, non-randomized trial suggest that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but additional studies are needed to determine whether these profiles can inform patient selection and new therapeutic approaches.

15 August 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CPChristine D. Palmer
Christine D. Palmer
ARAmy R. Rappaport
Amy R. Rappaport
MDMatthew J. Davis
Matthew J. Davis
MHMeghan G. Hart
Meghan G. Hart
CSCiaran D. Scallan
Ciaran D. Scallan
KJKarin Jooss
Karin Jooss

1 July 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
TSTakehito Shukuya
Takehito Shukuya
DCDavid P. Carbone
David P. Carbone

9 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
FSFerdinandos Skoulidis
Ferdinandos Skoulidis
HAHaniel A. Araujo
Haniel A. Araujo
MDMinh Truong Do
Minh Truong Do
YQYu Qian
Yu Qian
XSXin Sun
Xin Sun
JHJohn V. Heymach
John V. Heymach
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2. Here we show that patients with NSCLC who have mutations in the STK11 and/or KEAP1 tumour suppressor genes derived clinical benefit from dual ICB with the PD-L1 inhibitor durvalumab and the CTLA4 inhibitor tremelimumab, but not from durvalumab alone, when added to chemotherapy in the randomized phase III POSEIDON trial3. Unbiased genetic screens identified loss of both of these tumour suppressor genes as independent drivers of resistance to PD-(L)1 inhibition, and showed that loss of Keap1 was the strongest genomic predictor of dual ICB efficacy—a finding that was confirmed in several mouse models of Kras-driven NSCLC. In both mouse models and patients, KEAP1 and STK11 alterations were associated with an adverse tumour microenvironment, which was characterized by a preponderance of suppressive myeloid cells and the depletion of CD8+ cytotoxic T cells, but relative sparing of CD4+ effector subsets. Dual ICB potently engaged CD4+ effector cells and reprogrammed the tumour myeloid cell compartment towards inducible nitric oxide synthase (iNOS)-expressing tumoricidal phenotypes that—together with CD4+ and CD8+ T cells—contributed to anti-tumour efficacy. These data support the use of chemo-immunotherapy with dual ICB to mitigate resistance to PD-(L)1 inhibition in patients with NSCLC who have STK11 and/or KEAP1 alterations.

27 March 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ARAmy R. Rappaport
Amy R. Rappaport
CKChrisann Kyi
Chrisann Kyi
MLMonica Lane
Monica Lane
MHMeghan G. Hart
Meghan G. Hart
MJMelissa L. Johnson
Melissa L. Johnson
KJKarin Jooss
Karin Jooss